IDT Biologika to develop GMP manufacturing and make equity investment in ImVisioN
ImVisioN Therapeutics, a Swiss biopharmaceutical company pioneering allergy treatments, has agreed a manufacturing partnership with IDT Biologika, a contract manufacturer of vaccines and biopharmaceuticals.
IDT Biologika will take responsibility for all activities relating to manufacturing ImVisioN's product candidates. This includes the development of GMP manufacturing processes, production of GMP batches for clinical development, upscale and commercialisation of manufacturing processes and manufacturing products for commercial sale.
In addition, ImVisioN will be able to tap into IDT’s existing competences and capabilities relating to pharmaceutical product development (i.e. regulatory affairs, quality control and supply chain management). IDT Biologika also plans to make an equity investment in ImVisioN.
ImVisioN’s chief executive Martin Steiner says the company has completed the first human clinical study with its lead candidate CAT-MAT (IVN201) and plans to extend its product pipeline and bring additional product candidates, Birch-MAT and Mite-MAT, into clinical testing with the support of IDT Biologika within the next two to three years.